Anyone with an interest in lysosomal storage diseases is certain to focus this week on Bethesda, Md., where the FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review applications from two companies that have a long history of competing with each another. (BioWorld Today) Read More